Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Treatment of skin metastases of breast cancer (1999)
    Springer
    Cancer chemotherapy and pharmacology 44 (1999), S. S31 
    Details
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002800051115
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure (1996)
    Springer
    Cancer chemotherapy and pharmacology 38 (1996), S. 254-260 
    Details
    ISSN: 1432-0843
    Keywords: Key words Limited-sampling model ; Pharmacodynamics ; Pharmacokinetics ; Phase II ; Topotecan
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  Topotecan is a novel semisynthetic derivative of the anticancer agent camptothecin and inhibits the intranuclear enzyme topoisomerase I. The lactone structure of topotecan, which is in equilibrium with the inactive ring-opened hydroxy acid, is essential for this activity. We performed a pharmacokinetics study as part of phase II clinical trials in patients with various types of solid tumors, giving topotecan at 1.5 mg/m2 per day by 30-min infusion for 5 consecutive days, with courses being repeated every 3 weeks. Previously validated limited-sampling models, using concentration measurements in samples obtained 2 h after infusion, were used to calculate the area under the plasma concentration-time curves (AUCs) for both chemical forms. Samples were obtained from a total of 36 patients over 136 treatment days. The mean AUC of the closed-ring form (AUCclosed) was 8.74 (range 2.3–16.3)  μM min per day, and the mean AUC of the ring-opened form (AUCopen) was 11.5 (range 3.2–46.0)  μM min per day (interpatient variability 34–61%). In each patient the AUC values achieved on the 1st day of administration were similar to and, thus, predictive for those achieved during the following days, with a day-to-day variation of 7.39% being recorded for the AUCclosed and that of 12.6%, for the AUCopen. There was no drug accumulation during the 5 consecutive treatment days of each cycle. However, despite the large interpatient pharmacokinetic variability, the importance of regular drug monitoring on this schedule can be questioned, as the pharmacodynamic variability was relatively small.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002800050479
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Experience with independent radiological review during a topotecan trial in ovarian cancer (1997)
    Springer
    Annals of oncology 8 (1997), S. 463-468 
    Details
    ISSN: 1569-8041
    Keywords: independent radiological review ; measurable disease ; objective response rate ; ovarian carcinoma ; standard protocols
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: The results of phase II clinical trials are usually based onresponse of tumours to new oncolytic agents as evidenced by radiologicalimaging techniques. In this trial, all claimed responders were reviewed at aspecially convened meeting by the peer group of study investigators and aradiologist, independent of the study institutions. Patients and methods: One hundred eleven patients with advanced epithelialovarian cancer who had previously been treated with a platinum based regimenand had subsequently relapsed and who had measurable disease were treated withtopotecan at a dose of 1.5 mg/m2/day i.v. on five consecutivedays repeated every 21 days to assess efficacy and tolerability. Ninety-threewere considered eligible for the study per protocol and lesions were assessedby either computerised tomography (CT) or ultrasound (US). At the meeting,scans from all 24 (25.8%) claimed responders were reviewed, lesionsremeasured by the radiologist and a group discussion led to a final responseclassification. Results: Ninety-two patients were found to be eligible for the study and14 (15.2%) were confirmed as responders. Ten were rejected asresponders, mainly because the lesion did not decrease in size by≤50%, but one patient failed to meet the entry criteria.Remeasurement of CT scans was more objective than US scans. Difficulties wereencountered during review of some CT scan sequences because of non-uniformimaging parameters. Conclusions: Independent radiological review in conjunction with the peerreview group in this trial enabled rigorous and consistent application ofresponse criteria. This decreased the response rate from 25.8% to15.2%, but this represents a more objective assessment. CT scanning isan objective technique for assessing response rates in phase II studieswhereas US is subjective and dose not necessarily allow accurate lesionassessment on subsequent examinations, nor allows independent review at alater date. For these reasons it should not be used in such studies foraccurate lesion assessment. Cross-sectional imaging techniques such as CT andmagnetic resonance imaging (MRI) do allow accurate lesion assessment andindependent review at a later date, but standard protocols need to beinstituted, to allow consistency and a comparison to be made with subsequentstudies using the same agent and a broad comparison to be made with otheragents.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008241127883
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Single-agent gemcitabine versus cisplatin–etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer (1997)
    Springer
    Annals of oncology 8 (1997), S. 525-529 
    Details
    ISSN: 1569-8041
    Keywords: cisplatin ; etoposide ; gemcitabine ; non-small-cell lung cancer ; randomised phase II study
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: This randomised study was designed to determine the responserate, survival and toxicity of single-agent gemcitabine andcisplatin–etoposide in chemo-naïve patients with locally advancedor metastatic non-small-cell lung cancer. Patients and methods: Gemcitabine 1,000 mg/m2 was given asa 30 min intravenous infusion on days 1, 8, 15 of a 28-day cycle, cisplatin100 mg/m2 on day 1, and etoposide 100 mg/m2on days 1 (following cisplatin), 2 and 3. Major eligibility criteria includedhistologically confirmed non-small-cell lung cancer, measurable disease,Zubrod PS 0–2; no prior chemotherapy, no prior radiation of the measuredlesion, and no CNS metastases. Results: 146 patients were enrolled, 71 patients on gemcitabine and 75patients on cisplatin–etoposide. Patient characteristics were wellmatched across both arms. Sixty-six gemcitabine patients and 72cisplatin–etoposidepatients were evaluable. Partial responses were seen in 12 gemcitabinepatients (18.2%; 95% CI: 9.8–30) and 11cisplatin–etoposide patients (15.3%; 95% CI:7.9–25.7).Early indications show no statistical differences between the two treatmentswith respect to time to disease progression or survival. Haematological andlaboratory toxicity were moderate and manageable. However, hospitalisationbecause of neutropenic fever was required for 6 (8%)cisplatin–etoposide patients but not for any gemcitabine patients.Non-haematological toxicity was more pronounced with significant differencesin nausea and vomiting (grade 3 and 4: 11% gemcitabine vs. 29%cisplatin–etoposide; despite the allowance for 5-HT-3antiemetics during the first cycle of cisplatin–etoposide), and alopecia(grade 3 and 4: 3% gemcitabine vs. 62%cisplatin–etoposide). Conclusions: In this randomised study, single-agent gemcitabine was atleast as active but better tolerated than the combinationcisplatin–etoposide.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008207731111
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer (1997)
    Springer
    Annals of oncology 8 (1997), S. 351-354 
    Details
    ISSN: 1569-8041
    Keywords: carboplatin ; ovarian cancer ; paclitaxel ; phase II
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Recently the feasibility of combining carboplatin withpaclitaxel has been demonstrated in dose-finding studies. Maximum tolerateddoses were 550 mg/m2 and 200 mg/m2 (threehours), respectively. We report now a phase II study in ovarian cancerpatients. Patients and methods: Twenty-one chemo-naïve patients with optimally(n = 6) or suboptimally (n = 15) debulked stage III or IV ovarian cancer weretreated every three weeks for six courses with paclitaxel (200mg/m2) as a three-hour infusion, immediately followed bycarboplatin (550 mg/m2) as a 30-minute infusion. Results: Uncomplicated neutropenia was the principal toxicity, with mildanemia occurring regularly. As observed in the preceding phase I study, arelative lack of thrombocytopenia, generally grade III was found. Othertoxicities consisted of mild neurotoxicity, nausea and vomiting, alopecia,myalgia, and bone pain. All suboptimally debulked patients responded totherapy. Overall, 12 patients underwent second-look laparoscopy, whichrevealed a pathologically confirmed complete remission in six. The medianfollow-up interval at the time of analysis was 14 months. Twelve patients arecurrently free of progression, at 8+ to 19± months after the start oftherapy. Conclusion: The carboplatin/paclitaxel combination appears to be awell-tolerated regimen, yielding high response rates. This combination has nowgone forward to be evaluated in prospective randomized trials versus thecisplatin/paclitaxel combination.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008219618331
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Pharmacokinetics of 4′-epi-doxorubicin in man (1983)
    Springer
    Investigational new drugs 1 (1983), S. 59-64 
    Details
    ISSN: 1573-0646
    Keywords: anthracyclines ; 4′-epi-doxorubicin ; pharmacokinetics in man ; metabolism in man
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary The pharmacokinetics of 4′-epi-doxorubicin (4′-epi-adriamycin, 4′-epi-DX) in man can be described by a three-compartment model with a rapid distribution phase and a very long elimination phase. Urine excretion amounts to a total of about 11% of the administered dose during 48 h after drug administration, and less than 1% during the following 48 h. In plasma 4′-epi-doxorubicin is rapidly converted to five metabolites (4′-epi-doxorubicinol, aglycones and glucuronides), the concentration of the aglycones sometimes exceeding that of 4′-epi-DX. In urine only three metabolites were found in addition to the parent drug; they were identified as 4′-epi-doxorubicinol (EOH), 4′-epi-doxorubicin-glucuronide (E-Glu) and 4′-epi-doxorubicinol-glucuronide (EOH-Glu). Comparison of the pharmacokinetics and metabolic profiles of 4′-epi-DX and doxorubicin (DX) in man revealed that 4′-epi-DX eliminates faster than DX.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00180192
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...